Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

MASH: early-phase trial registry

4 of 6 indexed MASH trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

MASH: 6 US clinical trials tracked, 4 recruiting.

MASH is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Pichamol Jirapinyo, MD, MPH, running 1 of these trials.

Enrollment posture brief

Registry condition mash

OPEN 4 | RECR 67% | LATE 0 | EARLY 3 | RANK #2866 | SPON 1

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

MASH (this)67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near MASH

MASH lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for MASH on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. MASH is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates MASH research.

    Pichamol Jirapinyo, MD, MPH accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical MASH enrolment sits around 132 participants.

    Median target enrolment is 132 among the 6 trials that report a genuine target (sentinel values excluded). 1 of those (16.7%) plan for fewer than 100 participants.

  4. MASH splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 22

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2

Named interventions

Most-linked intervention names on MASH records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
2 trials
ALG-055009 Drug
1 trials
RO7790121 Drug
1 trials
Digoxin Drug
1 trials
Lifestyle modification Behavioral
1 trials
ESG + lifestyle modification Device
1 trials
Endothelial cell collection Other
1 trials
Liver biopsy Device
1 trials

US sites by state

Facility locations filed on MASH trials. A trial with sites in several states counts in each.

Massachusetts 2 trials
Georgia 2 trials
Florida 2 trials
Arizona 2 trials
West Virginia 1 trials
Washington 1 trials
Texas 1 trials
Tennessee 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this MASH page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This MASH condition card totals 6 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.